Tomorrow's Earnings Reports

NanoViricides (NYSE: NNVC) advanced this week as its lead antiviral candidate NV-387 received FDA Orphan Drug and Rare Pediatric Disease designations for Measles, opening a path toward a Priority Review Voucher. Noble Capital Markets initiated coverage on NNVC with an Outperform rating and a 6 price target, citing the company's broad-spectrum antiviral platform designed to address Measles, Mpox, Ebola, and future outbreaks.

Our research analysts are set to release their next stock idea tomorrow morning just before 12:00 PM Eastern. Don't miss your chance to be the first to see our next stock pick.

Looking for better stock ideas? Sign-up to receive The Early Bird Stock of the Day. Each day, MarketBeat's team of expert research analysts identifies one compelling stock and provides both a bull case and a bear case for each company.

Once you turn 73, the IRS requires you to take distributions from your IRA, 401(k), and other retirement accounts - and without a plan, those required minimum distributions can carry a serious tax cost. SmartAsset's model suggests working with a fiduciary financial advisor could potentially add 36% to 212% more dollar value to a portfolio over a lifetime. Their no-cost tool matches you with vetted advisors in your area who are legally bound to act in your interest.

A scheduled announcement on July 31st could reshuffle the stock market's winners and losers - and one lesser-known name may be positioned to benefit while the Magnificent 7 stumbles. Smaller, overlooked stocks are showing growing potential to challenge AI's biggest players. One specific ticker stands out heading into that date.